The group's principal activity is the research, development and commercialization of drugs for the treatment of various cancers. The group has a portfolio of six anti-cancer drugs which are in clinical trials. The group has two novel proprietary technology platforms for drug portfolio: the proprietary neolipid(TM) liposomal drug delivery platform and a tumor-targeting platform. The platforms are used for the treatment of various forms of cancer and brain tumors. The group develops liposome encapsulated doxorubicin (led), liposome encapsulated paclitaxel (lep) liposome encapsulated antisene oligonucleotides (le-aon) and liposome encapsulated mitoxantrone (lem). The group operates solely in the domestic market.
